Get startedLog in
    Picture of OliX Pharmaceuticals logo

    226950 — OliX Pharmaceuticals Income Statement

    0.000.00%
    kr flag iconLast trade - 00:00
    HealthcareHighly SpeculativeMid CapMomentum Trap
    Balance sheetIncome statementCashflow
    Subscribe to view all data

    Annual income statement for OliX Pharmaceuticals, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.

    2020
    December 31st
    R2021
    December 31st
    2022
    December 31st
    2023
    December 31st
    2024
    December 31st
    Period Length:12 M12 M12 M12 M12 M
    Source:Annual Audited AccountsAnnual Audited AccountsAnnual Audited AccountsAnnual Audited AccountsAnnual Audited Accounts
    Standards:
    IFRS
    IFRS
    IFRS
    IFRS
    IFRS
    Status:FinalFinalFinalFinalFinal
    Revenue
    Total Revenue2,4743,6749,32017,0645,677
    Selling / General / Administrative Expenses
    Research And Development
    Depreciation and Amortization
    Unusual Expense / Income
    Other Operating Expenses
    Total Operating Expenses18,71627,61431,69634,82844,291
    Operating Profit-16,241-23,939-22,376-17,764-38,614
    Gain / Loss on Sale of Assets
    Total Net Non Operating Interest Income / Expense
    Other Net Non Operating Costs
    Net Income Before Taxes-20,511-29,997-29,108-18,170-41,071
    Provision for Income Taxes
    Net Income After Taxes-19,385-29,176-28,113-19,102-40,659
    Minority Interest
    Net Income Before Extraordinary Items
    Extraordinary Items
    Net Income-19,385-29,715-19,495-19,102-40,659
    Income Available to Common Shareholders Excluding Extraordinary Items
    Income Available to Common Shareholders Including Extraordinary Items
    Dilution Adjustment
    Diluted Net Income-19,385-29,715-19,495-19,102-40,659
    Diluted Weighted Average Shares
    Basic EPS Including Extraordinary Items
    Diluted EPS Including Extraordinary Items
    Diluted EPS Excluding Extraordinary Items
    Normalised Income Before Taxes
    Normalised Income After Taxes
    Normalised Income Available to Common Shareholders
    Diluted Normalised EPS-1,474-2,099-1,878-1,339-2,181
    Dividends per Share